Carcinoma, Ovarian Epithelial

The supplied grounding supports an association with mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1. No single environmental or infectious cause is supported in the grounding. The disease is also discussed as a heterogeneous group of tumors with different histologic subtypes.

The disease is characterized by malignant transformation of ovarian surface epithelial cells, with subtype-specific pathology. Grounding also supports involvement of apoptosis-related biology and drug resistance, particularly in recurrent or treatment-refractory disease. The tumor microenvironment, low tumor-infiltrating lymphocyte density, and immune checkpoint pathway regulation are described as contributors to resistance to immune-based therapy.

The strongest supported risk factor in the grounding is the presence of pathogenic mutations in ovarian cancer-associated genes such as BRCA1 and CDH1, along with other listed genes. Advanced-stage presentation is common, but that is a disease characteristic rather than a predisposing factor. No additional epidemiologic risk factors are directly supported by the supplied material.

Standard treatment is surgical cytoreduction, with the goal of complete resection, followed by adjuvant chemotherapy. The grounding supports platinum-based chemotherapy, including carboplatin and paclitaxel, as core drug classes used in treatment. Genetic testing is described as standard of care, and selected recurrent or platinum-resistant disease may be treated with targeted therapy such as folate receptor alpha-directed antibody-drug conjugates and anti-angiogenic therapy such as bevacizumab.